Spontaneous Coronary Artery Dissection National Swiss Registry
Launched by DR. SOPHIE DEGRAUWE · Jun 30, 2020
Trial Information
Current as of August 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Spontaneous Coronary Artery Dissection National Swiss Registry, also known as the SwissSCAD registry, is a research study focused on understanding a condition called spontaneous coronary artery dissection (SCAD). This condition mainly affects younger women who usually don’t have typical heart disease risk factors. SCAD can lead to serious heart problems, like heart attacks or even sudden cardiac arrest. The goal of this study is to learn more about how SCAD develops, its outcomes, and the different treatments available.
If you're an adult aged 18 or older and have been diagnosed with SCAD recently or within the last five years, you might be eligible to participate. To join the study, you would need to agree to take part by signing an informed consent form. Participants will be monitored over time, helping researchers gather important information about SCAD. This study is a chance to contribute to a better understanding of SCAD, which is still not very well known, and to help improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject is ≥18 years of age.
- • Patient presenting newly diagnosed SCAD or diagnosed with SCAD within the last 5 years.
- • Subject must be willing to sign a Patient Informed Consent (PIC).
- Exclusion Criteria:
- • Patient unwilling or unable to provide informed consent.
- • Patients with atherosclerotic or iatrogenic coronary dissection.
About Dr. Sophie Degrauwe
Dr. Sophie Degrauwe is a distinguished clinical trial sponsor with a robust background in medical research and a commitment to advancing healthcare through innovative studies. With extensive experience in overseeing clinical trials across various therapeutic areas, Dr. Degrauwe emphasizes rigorous scientific methodology, patient safety, and ethical standards. Her leadership fosters collaboration among multidisciplinary teams, ensuring that trials are conducted efficiently and effectively to generate reliable data that contributes to the development of new therapies. Dr. Degrauwe's dedication to enhancing patient outcomes positions her as a key figure in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Geneva, , Switzerland
Patients applied
Trial Officials
Sophie Degrauwe, Dr
Principal Investigator
Hopitaux universitaires de Geneve
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials